Live
- New Delhi: 9 arrested for duping people of Rs 2.38 cr
- Graffiti ‘threatening’ Kejriwal appears inside metro trains
- Drunk Man Attacks Hospital Staff in Srikakulam District
- Baramulla LS seat: Pandits vote for dedicated township in valley
- PM not doing ‘Hindu-Muslim’ politics but telling truth: Dhami
- WhatsApp Update: WhatsApp to Automatically Clear Unread Messages: How to Enable It
- 18 per cent of teens drink caffeine to stay awake
- Narasimha Jayanti 2024: Date, Puja Timings, Rituals, History, and Significance
- Using learning analytics to enhance teaching and learning in higher education
- International Tea Day 2024: Date, History, Significance, and Celebration Tips
Granules Pharma gets nod for Colchicine drug
Granules India on Thursday said its wholly-owned foreign arm has received US health regulator's approval for Colchicine tablets, used in the treatment of familial Mediterranean fever.
Hyderabad: Granules India on Thursday said its wholly-owned foreign arm has received US health regulator's approval for Colchicine tablets, used in the treatment of familial Mediterranean fever.
Familial Mediterranean fever is a genetic disorder that causes recurrent episodes of fever that are typically accompanied by pain in the abdomen, chest, or joints. "The US Food & Drug Administration (USFDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc, a wholly-owned foreign subsidiary of Granules India Ltd for Colchicine tablets USP, 0.6 mg," the company said in a regulatory filing. The filing further said that "it is bioequivalent to the reference listed drug product (RLD), Colcrys tablets, 0.6 mg, of Takeda Pharmaceuticals USA, Inc."
